Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

[1]  Sung-Bae Kim,et al.  Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial , 2022, The Lancet.

[2]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[3]  Y. Bang,et al.  HER2-targeted therapies — a role beyond breast cancer , 2019, Nature Reviews Clinical Oncology.

[4]  A. Jager,et al.  Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab? , 2019, Breast Cancer Research and Treatment.

[5]  A. Rowland,et al.  Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel , 2019, Front. Oncol..

[6]  W. Tsuji,et al.  Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series , 2018, International journal of surgery case reports.

[7]  Christine Y. Lu,et al.  Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016) , 2018, Breast Cancer Research and Treatment.

[8]  E. Romond,et al.  Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  F. Jänicke,et al.  Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry , 2014, BMC Cancer.

[10]  D. Rayson,et al.  Trastuzumab Beyond Progression for HER2 Positive Metastatic Breast Cancer: Progression‐Free Survival on First‐Line Therapy Predicts Overall Survival Impact , 2014, The breast journal.

[11]  S. Barni,et al.  A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. , 2013, Clinical breast cancer.

[12]  R. O'Regan,et al.  The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy , 2012, Chemotherapy research and practice.

[13]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[14]  S. Loibl,et al.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Moasser.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.

[16]  Michael Gnant,et al.  Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F. Cognetti,et al.  HER2/neu role in breast cancer: from a prognostic foe to a predictive friend , 2007, Current opinion in obstetrics & gynecology.

[18]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[19]  P. Ellis,et al.  Adjuvant trastuzumab for HER2-positive breast cancer , 2005, The Lancet.

[20]  A. Shimomura,et al.  Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis , 2017, Breast Cancer Research and Treatment.